Business Wire

IRAP/EUROPEAN-PIRATES

Share
Institute for Rational Drug Policies and European Pirate Party Call on European Commission to Implement Harm Reduction Policies to Help European Citizens Make Positive Lifestyle Choices

A webinar on Citizen Focused Disease Prevention, organised by the Institute for Rational Drug Policies (IRAP) in cooperation with the European Pirates, established that harm reduction policies should be used to help people with a wide range of addictions, including smoking.

“We support the concept of harm reduction. Pirates emphasise the need to focus long-term attention on drug use and addictions,” said Mikuláš Peksa, Czech Green MEP. “We are working on a long-term prevention programme of minimising risks at the national level and at the European level. We must also consider how to minimise the negative impact of government drug policies and laws, and this point of view should also be followed by the European Commission.”

The European Commission currently fails to recognise the potential of harm reduction policies even though there is clear public support for them as shown by the recent Town Hall organised by the Commission on Europe's Beating Cancer Plan. Despite harm reduction being perceived by the Town Hall audience as being extremely important, the Commission still refuses to take harm reduction seriously.

According to Jindrich Voboril, Head of IRAP and former long-term National Anti-Drug Coordinator in the Czech Republic: “We have to consider harm reduction not only as a type of social or health service but as a complex approach that should also be incorporated into law and drug policies.”

Advising how to embrace harm reduction into practice: “One part of it is changing the European Commission’s structure. How can we be effective when illicit drugs are solved with one set of criteria, licit drugs with another and problem gambling is left aside altogether? The current situation does not allow effective solution to drug policies and it is hardly cost-effective. The structure of the Directorate General must be changed and the mandate of the EMCDDA (European Monitoring Centre for Drugs and Drug Addictions) must be strengthened. In the context of the ongoing debate on Europe’s Beating Cancer Plan, it’s time that the European Commission begins to take the concept of harm reduction seriously,” concluded Voboril.

“Harm reduction is a broad concept that can complement other approaches, for example when tackling addiction,” said Kasia Kowalczyk from The Global Public Health Network alongside her colleague David Mackintosh. “Harm Reduction has untapped potential across different areas of public health. It works best through a collaborative approach and engages the beneficiaries of public health services or other interventions.”

During the discussion, Hana Horka from the European Commission’s DG SANTE was not enthusiastic about harmonising approaches to addiction. Ms. Horka, despite endorsing harm reduction policies for drug addiction, did not endorse harm reduction policies for tobacco or alcohol, instead advocating for tax increases and prohibitive measures on tobacco products.

Abstinence should not be regarded as the only option for addicts. The goal of harm reduction policies is to keep people alive, help them to make positive changes in their lives and offer them alternatives that cause less harm.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release

Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit

I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release

I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu

WEF26: Saudi Arabia Leads New Global Push to Protect Coral Reefs, Unlock AI Potential22.1.2026 05:52:00 CET | Press release

The Saudi delegation to the World Economic Forum (WEF) Annual Meeting 2026 today observed a series of announcements aimed at addressing urgent global challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121465066/en/ Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced at the World Economic Forum Annual Meeting that Saudi Arabia will host the first Global Coral Reef Summit in 2026 (Photo: AETOSWire) Her Royal Highness Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States of America, announced that Saudi Arabia will host the first Global Coral Reef Summit in 2026, bringing together global leaders, scientists, and investors to drive solutions for the protection and recovery of coral reef ecosystems. The summit will address key challenges and policy and regulatory gaps, develop science-based sol

BitGo Holdings Announces Pricing of Initial Public Offering22.1.2026 03:38:00 CET | Press release

BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, announced today the pricing of its initial public offering of an aggregate of 11,821,595 shares of Class A common stock at a price to the public of $18.00 per share. The offering consists of 11,026,365 shares of Class A common stock being offered by BitGo and 795,230 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo has granted the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on January 22, 2026 under the ticker symbol "BTGO" and the offering is expected to close on January 23, 2026, subject to customary closin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye